The results of the phase III PACIFIC trial (NCT02125461) established the current standard of care for patients with unresectable stage III NSCLC: platinum-based concurrent chemoradiotherapy (cCRT) followed by consolidation treatment with the anti-PD-L1 monoclonal antibody Durvalumab for 1 year (Antonia et al., 2017; 2018). The gene discussed is CD274; the disease is non-small cell lung carcinoma.